Literature DB >> 20219919

Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif.

Robert C Walker1, Mohammad A Khan, Sandra Kao, Ritu Goila-Gaur, Eri Miyagi, Klaus Strebel.   

Abstract

APOBEC3G (A3G) is a host cytidine deaminase that serves as a potent intrinsic inhibitor of retroviral replication. A3G is packaged into human immunodeficiency virus type 1 virions and deaminates deoxycytidine to deoxyuridine on nascent minus-strand retroviral cDNA, leading to hyper-deoxyguanine-to-deoxyadenine mutations on positive-strand cDNA and inhibition of viral replication. The antiviral activity of A3G is suppressed by Vif, a lentiviral accessory protein that prevents encapsidation of A3G. In this study, we identified dominant negative mutants of Vif that interfered with the ability of wild-type Vif to inhibit the encapsidation and antiviral activity of A3G. These mutants were nonfunctional due to mutations in the highly conserved HCCH and/or SOCS box motifs, which are required for assembly of a functional Cul5-E3 ubiquitin ligase complex. Similarly, mutation or deletion of a PPLP motif, which was previously reported to be important for Vif dimerization, induced a dominant negative phenotype. Expression of dominant negative Vif counteracted the Vif-induced reduction of intracellular A3G levels, presumably by preventing Vif-induced A3G degradation. Consequently, dominant negative Vif interfered with wild-type Vif's ability to exclude A3G from viral particles and reduced viral infectivity despite the presence of wild-type Vif. The identification of dominant negative mutants of Vif presents exciting possibilities for the design of novel antiviral strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20219919      PMCID: PMC2863814          DOI: 10.1128/JVI.02318-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  78 in total

1.  The tyrosine kinase Hck is an inhibitor of HIV-1 replication counteracted by the viral vif protein.

Authors:  G Hassaïne; M Courcoul; G Bessou; Y Barthalay; C Picard; D Olive; Y Collette; R Vigne; E Decroly
Journal:  J Biol Chem       Date:  2001-02-27       Impact factor: 5.157

2.  Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.

Authors:  Xianghui Yu; Yunkai Yu; Bindong Liu; Kun Luo; Wei Kong; Panyong Mao; Xiao-Fang Yu
Journal:  Science       Date:  2003-10-16       Impact factor: 47.728

3.  Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.

Authors:  Andrew Mehle; Joao Goncalves; Mariana Santa-Marta; Mark McPike; Dana Gabuzda
Journal:  Genes Dev       Date:  2004-12-01       Impact factor: 11.361

4.  Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.

Authors:  Bin Yang; Ling Gao; Lin Li; Zhixian Lu; Xuejun Fan; Charvi A Patel; Roger J Pomerantz; Garrett C DuBois; Hui Zhang
Journal:  J Biol Chem       Date:  2002-12-11       Impact factor: 5.157

5.  Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.

Authors:  Bärbel Schröfelbauer; Tilo Senger; Gerard Manning; Nathaniel R Landau
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.

Authors:  M A Khan; C Aberham; S Kao; H Akari; R Gorelick; S Bour; K Strebel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 7.  Human cellular restriction factors that target HIV-1 replication.

Authors:  Klaus Strebel; Jeremy Luban; Kuan-Teh Jeang
Journal:  BMC Med       Date:  2009-09-16       Impact factor: 8.775

8.  A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G.

Authors:  Gongying Chen; Zhiwen He; Tao Wang; Rongzhen Xu; Xiao-Fang Yu
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.

Authors:  Sandrine Opi; Sandra Kao; Ritu Goila-Gaur; Mohammad A Khan; Eri Miyagi; Hiroaki Takeuchi; Klaus Strebel
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

Review 10.  HIV-1 Vif, APOBEC, and intrinsic immunity.

Authors:  Ritu Goila-Gaur; Klaus Strebel
Journal:  Retrovirology       Date:  2008-06-24       Impact factor: 4.602

View more
  22 in total

Review 1.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

2.  Dissection of the HIV Vif interaction with human E3 ubiquitin ligase.

Authors:  Leslie S Wolfe; Bradford J Stanley; Chang Liu; William K Eliason; Yong Xiong
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

3.  Identification of a Cullin5-ElonginB-ElonginC E3 complex in degradation of feline immunodeficiency virus Vif-mediated feline APOBEC3 proteins.

Authors:  Jiawen Wang; Wenyan Zhang; Mingyu Lv; Tao Zuo; Wei Kong; Xianghui Yu
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

4.  Hydrodynamic and functional analysis of HIV-1 Vif oligomerization.

Authors:  Stephen M Techtmann; Rodolfo Ghirlando; Sandra Kao; Klaus Strebel; Ernest L Maynard
Journal:  Biochemistry       Date:  2012-03-05       Impact factor: 3.162

5.  A mutant Tat protein provides strong protection from HIV-1 infection in human CD4+ T cells.

Authors:  Ann Apolloni; Min-Husan Lin; Haran Sivakumaran; Dongsheng Li; Michael H R Kershaw; David Harrich
Journal:  Hum Gene Ther       Date:  2013-03-01       Impact factor: 5.695

6.  Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.

Authors:  Ying Dang; Xiaojun Wang; Ian A York; Yong-Hui Zheng
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

7.  Crystal structure of an antiviral ankyrin targeting the HIV-1 capsid and molecular modeling of the ankyrin-capsid complex.

Authors:  Warachai Praditwongwan; Phimonphan Chuankhayan; Somphot Saoin; Tanchanok Wisitponchai; Vannajan Sanghiran Lee; Sawitree Nangola; Saw See Hong; Philippe Minard; Pierre Boulanger; Chun-Jung Chen; Chatchai Tayapiwatana
Journal:  J Comput Aided Mol Des       Date:  2014-07-05       Impact factor: 3.686

Review 8.  HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.

Authors:  Guangdi Li; Erik De Clercq
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-29       Impact factor: 11.056

9.  CBFβ enhances de novo protein biosynthesis of its binding partners HIV-1 Vif and RUNX1 and potentiates the Vif-induced degradation of APOBEC3G.

Authors:  Eri Miyagi; Sandra Kao; Venkat Yedavalli; Klaus Strebel
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

10.  An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.

Authors:  Ryan P Bennett; Ryan A Stewart; Priscilla A Hogan; Roger G Ptak; Marie K Mankowski; Tracy L Hartman; Robert W Buckheit; Beth A Snyder; Jason D Salter; Guillermo A Morales; Harold C Smith
Journal:  Antiviral Res       Date:  2016-11-05       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.